A meta-analysis showed that women with BRCAm (not specified if somatic mutation carriers are included) OC have an increased OS (BRCA1: HR 0.76, 95% CI: 0.70–0.83; BRCA2: HR: 0.58, 95% CI: 0.50–0.66), regardless of tumour stage, grade, or histologic subtype [29]. The gene discussed is BRCA2; the disease is neoplasm.